Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.
Author:
- Lisa A RaedlerLRLisa A Raedler
- 1 March 2015
- journal article
- Vol. 8, 75-9
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2011
- Kinase drug discovery approaches in chronic myeloproliferative disordersOncogene, 2009
- Evidence and expertise in the management of polycythemia vera and essential thrombocythemiaLeukemia, 2008
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisalLeukemia, 2008
- Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapyAmerican Journal of Hematology, 2008
- Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersBlood, 2006
- Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic ImplicationsSeminars in Thrombosis and Hemostasis, 2006
- Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational studyBlood, 2005
- Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia VeraJournal of Clinical Oncology, 2005
- Polycythemia vera: myths, mechanisms, and managementBlood, 2002